Key Highlights
- Recursion aligned with the FDA on the design of a registrational Phase 3 trial of REC-4881 in familial adenomatous polyposis.
- The primary endpoint is a composite event-free survival measure that includes excision of adenomas 10 mm or larger.
- The trial is expected to enrol about 200 adults and is on track to begin in the second half of 2027.
- FAP has no approved pharmacologic therapies, and the company said REC-4881 is among the first AI-enabled programs to reach this stage.
Recursion (NASDAQ:RXRX), a clinical-stage company applying AI to drug discovery and development, announced on 18 November 2026 that it has aligned with the US Food and Drug Administration on the design of a registrational Phase 3 trial of REC-4881. The investigational oral MEK1/2 inhibitor is being developed for familial adenomatous polyposis, a hereditary condition that causes polyps in the gastrointestinal tract.
The company said the alignment is a regulatory milestone for a disease that currently has no approved pharmacologic therapies.
Trial Design and Endpoints
The composite event-free survival primary endpoint includes a novel component: excision of an adenoma 10 mm or larger in the upper or lower gastrointestinal tract. Recursion said adenomas of this size are associated with an increased risk of high-grade dysplasia and cancer.
Modified Spigelman stage progression and total polyp burden will be included among the secondary endpoints. The trial is expected to enrol about 200 adults following colectomy or proctocolectomy.
Development Background
The company said REC-4881’s potential as a first-in-class oral therapy was identified through unbiased phenotypic screening using Recursion’s AI foundation models. The company describes it as among the first AI-enabled programs to advance a registrational Phase 3 design for a disease with no approved therapies.
The release does not report clinical efficacy data from the Phase 3 trial, which has not yet started.
Timing and Regulatory Status
Recursion said the trial is on track to begin in the second half of 2027. The FDA alignment covers trial design rather than any approval, and the company will need to complete the study and any regulatory review before the drug could be marketed.
The announcement did not provide development costs, funding plans or the expected Revenue from REC-4881.
Final Word
Recursion has secured FDA alignment on a Phase 3 design for REC-4881, including a novel endpoint focused on clinically meaningful adenoma removal. The step moves the program toward a registrational trial that is not due to begin until the second half of 2027.
The design still has to deliver results in roughly 200 patients, and the company has not yet reported data from the registrational study. Further updates will be needed before the program’s clinical and regulatory outcomes can be assessed.






Please wait processing your request...